Overview

It is the broad, long-term goal of this program to build on and extend the current knowledge in the field of bone marrow transplantation and hematological malignancies.  This program is a multidisciplinary clinical, basic and translational research effort whose overall goal is to improve outcomes for patients with solid and liquid malignancies. To this end, the investigators of this application will utilize the approach of translational research, bridging the novel experimental concepts and observations made at the laboratory bench to clinical application at the patients’ bedsides. In both basic and clinical areas, the HCTHM Program fosters interactions between many Programs and members of the DCCC.  The Program includes 35 members from 11 basic and clinical departments within Duke University. T From 2004-2008, program members published 859 papers in peer-reviewed journals cited in PubMed. Of these publications, 6.3% are the result of intra-programmatic collaborations and 12.9% due to inter-programmatic collaborations.
The aims of the Program are:
1.    To optimize the use of allogeneic and autologous transplantation of hematopoietic stem cells.
2.    To use and compare various alternative sources of hematopoietic stem cells for allogeneic transplantation.
3.    To develop novel preparatory regimens for allogeneic stem cell transplantation.
4.    To understand the basic biology of graft versus tumor (GvT) and to explore new ways to induce GvT effects following transplantation.
5.    To study the nature of and define the problems associated with hematopoietic and immunologic reconstitution after allogeneic transplantation with the overall goal of developing novel supportive care measures for patients transplanted with stem cells from alternative and mismatched donors.
6.    To understand hematopoietic stem cell development and control of differentiation.
7.    To promote effective interactions of the members of the Duke Comprehensive Cancer Center that will stimulate new translational research efforts to improve the care of patients with hematologic malignancies.
8.    To identify new cellular and stromal targets for therapy with antibodies or small molecules, leading to evaluation of various labeling techniques, such as using radiolabels or diphtheria toxins, of small molecules and antibodies with subsequent clinical evaluation of safety and efficacy.
9.    To evaluate the importance of different signaling mechanisms in leukemogenesis or lymphomagenesis.

Pediatric Division of Blood and Marrow Transplantation

Adult Bone Marrow & Stem Cell Transplant Program

High-Impact Journal Publications

Below are recent publications in high-impact journals from Cancer Center members in this program. To see journal articles for a particular member, click on the researcher's name in the Membership section.

---

O'Brien S,Moore JO,Boyd TE,Larratt LM,Skotnicki AB,Koziner B,Chanan-Khan AA,Seymour JF,Gribben J,Itri LM,Rai KR. 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen., . Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]

Kuderer NM,Ortel TL,Francis CW. Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival., . Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]

Anguiano A,Tuchman SA,Acharya C,Salter K,Gasparetto C,Zhan F,Dhodapkar M,Nevins J,Barlogie B,Shaughnessy JD Jr,Potti A. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma., , (4197-203) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]

Song J,Bishop BL,Li G,Grady R,Stapleton A,Abraham SN. TLR4-mediated expulsion of bacteria from infected bladder epithelial cells., . Proceedings of the National Academy of Sciences of the United States of America Abstract [More ...]

Read TA,Fogarty MP,Markant SL,McLendon RE,Wei Z,Ellison DW,Febbo PG,Wechsler-Reya RJ. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma., , (135-47) - Cancer cell Abstract [More ...]

Aiuti A,Cattaneo F,Galimberti S,Benninghoff U,Cassani B,Callegaro L,Scaramuzza S,Andolfi G,Mirolo M,Brigida I,Tabucchi A,Carlucci F,Eibl M,Aker M,Slavin S,Al-Mousa H,Al Ghonaium A,Ferster A,Duppenthaler A,Notarangelo L,Wintergerst U,Buckley RH,Bregni M,Marktel S,Valsecchi MG,Rossi P,Ciceri F,Miniero R,Bordignon C,Roncarolo MG. Gene therapy for immunodeficiency due to adenosine deaminase deficiency., , (447-58) - The New England journal of medicine Abstract [More ...]

Zhao C,Chen A,Jamieson CH,Fereshteh M,Abrahamsson A,Blum J,Kwon HY,Kim J,Chute JP,Rizzieri D,Munchhof M,VanArsdale T,Beachy PA,Reya T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia., . Nature Abstract [More ...]

Lenz G,Wright GW,Emre NC,Kohlhammer H,Dave SS,Davis RE,Carty S,Lam LT,Shaffer AL,Xiao W,Powell J,Rosenwald A,Ott G,Muller-Hermelink HK,Gascoyne RD,Connors JM,Campo E,Jaffe ES,Delabie J,Smeland EB,Rimsza LM,Fisher RI,Weisenburger DD,Chan WC,Staudt LM. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways., , (13520-5) - Proceedings of the National Academy of Sciences of the United States of America Abstract [More ...]

Yang ZJ,Ellis T,Markant SL,Read TA,Kessler JD,Bourboulas M,Schüller U,Machold R,Fishell G,Rowitch DH,Wainwright BJ,Wechsler-Reya RJ. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells., , (135-45) - Cancer cell Abstract [More ...]

Shaffer AL,Emre NC,Lamy L,Ngo VN,Wright G,Xiao W,Powell J,Dave S,Yu X,Zhao H,Zeng Y,Chen B,Epstein J,Staudt LM. IRF4 addiction in multiple myeloma., , (226-31) - Nature Abstract [More ...]

---

Click here for these and other high-impact publications in this research program.